[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2007012947A - Composiciones biomejoradas. - Google Patents

Composiciones biomejoradas.

Info

Publication number
MX2007012947A
MX2007012947A MX2007012947A MX2007012947A MX2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A MX 2007012947 A MX2007012947 A MX 2007012947A
Authority
MX
Mexico
Prior art keywords
arb
composition
solubility
solubility enhancing
present
Prior art date
Application number
MX2007012947A
Other languages
English (en)
Inventor
Nagesh R Palepu
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Paras R Jain
Original Assignee
Rubicon Res Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Pvt Ltd filed Critical Rubicon Res Pvt Ltd
Publication of MX2007012947A publication Critical patent/MX2007012947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion, se relaciona con un metodo para aumentar la biodisponibilidad de Bloqueadores del Receptor de Angiotensina II (ARBs) al preparar una composicion de un ARB con al menos un agente para intensificar la solubilidad. En particular, la presente invencion se relaciona con agentes para intensificar la solubilidad que no solo actuen como intensificadores de solubilidad sino que tambien mejoran la velocidad de disolucion, particularmente en medios acidos o medianamente acidos, donde es minima la solubilidad del ARB. En la composicion, el ARB puede estar presente en la forma de una combinacion fisica, una dispersion, solucion o complejo de solidos con el agente para intensificar la solubilidad. La composicion de un ARB con el agente para intensificar la solubilidad se puede incorporar en una formulacion para liberacion inmediata o una liberacion controlada o cualquier otra liberacion modificada adecuada. Las formas de osificacion para liberacion inmediata que contienen la composicion de un ARB proporcionan una liberacion in vitro de al menos el 40% en medios acidos (pH < 3). Como resultado, la biodisponibilidad del ARB se puede aumentar en al menos un 20% segun se mide mediante Cmax, AUC0-t y AUCo-8.
MX2007012947A 2005-04-18 2006-04-18 Composiciones biomejoradas. MX2007012947A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN477MU2005 2005-04-18
IN315MU2006 2006-03-06
PCT/US2006/014422 WO2006113631A2 (en) 2005-04-18 2006-04-18 Bioenhanced compositions

Publications (1)

Publication Number Publication Date
MX2007012947A true MX2007012947A (es) 2008-04-09

Family

ID=37115820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012947A MX2007012947A (es) 2005-04-18 2006-04-18 Composiciones biomejoradas.

Country Status (8)

Country Link
EP (1) EP1877042A4 (es)
JP (1) JP2008536929A (es)
KR (1) KR20080042039A (es)
AU (1) AU2006236497A1 (es)
CA (1) CA2605183A1 (es)
IL (1) IL186721A0 (es)
MX (1) MX2007012947A (es)
WO (1) WO2006113631A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077581A2 (en) * 2006-01-02 2007-07-12 Rubicon Research Private Limited Pharmaceutical compositions
KR20090049089A (ko) * 2006-09-05 2009-05-15 아스트라제네카 아베 칸데사르탄 실렉세틸을 포함하는 약학 조성물
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
EP2083799A1 (en) * 2006-10-20 2009-08-05 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
US20100041644A1 (en) * 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
AR064104A1 (es) * 2006-12-05 2009-03-11 Novartis Ag Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
WO2008134013A2 (en) * 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical excipient complex
WO2008149338A2 (en) * 2007-06-06 2008-12-11 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
RU2010104960A (ru) * 2007-08-01 2011-09-10 Тева Фармасьютикал Индастриес Лтд. (Il) Фармацевтическая композиция кандесартана
CA2701695A1 (en) * 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
JP2011500647A (ja) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Ｎ−アリール尿素系化合物を含む固体分散体生成物
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
KR20100119578A (ko) * 2008-02-28 2010-11-09 노파르티스 아게 발사르탄 고체 경구 투여 형태 및 이러한 제형물의 제조 방법
BRPI0913337A2 (pt) * 2008-06-03 2017-05-23 Novartis Ag liberação pulsátil de valsartan
DK2165702T3 (da) 2008-09-17 2012-03-05 Helm Ag Stabile og let opløselige sammensætninger af candesartancilexetil fremstillet ved vådgranulering
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
CN102802611B (zh) * 2009-06-25 2014-11-12 进洋制药株式会社 含氯沙坦羧酸的药物组合物及其生产方法
WO2011028016A2 (ko) * 2009-09-04 2011-03-10 한올바이오파마주식회사 베타 아드레날린 차단제와 안지오텐신-2 수용체 길항제를 포함하는 약제학적제제
CA2864088C (en) * 2012-02-08 2020-04-28 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
WO2014088123A1 (en) 2012-12-05 2014-06-12 Sawai Pharmaceutical Co., Ltd. Candesartan cilexetil-containing preparation
WO2014119667A1 (ja) 2013-01-30 2014-08-07 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
SG11202002864PA (en) 2017-10-04 2020-04-29 Celgene Corp Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl] amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN109350609A (zh) * 2018-11-14 2019-02-19 常州大学 一种壳聚糖包裹玉米醇溶蛋白纳米粒的制备及负载金合欢素钠盐的应用
CN113933472B (zh) * 2020-06-29 2024-07-09 武汉武药科技有限公司 测定替米沙坦固体制剂溶出度的溶出介质及其应用
CN112516105A (zh) * 2020-12-10 2021-03-19 成都恒瑞制药有限公司 一种氯沙坦钾口服制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
EP1575581A1 (en) * 2002-12-18 2005-09-21 Novartis AG Combinations of valsartan with cox-2 inhibitors
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin

Also Published As

Publication number Publication date
EP1877042A4 (en) 2011-03-02
JP2008536929A (ja) 2008-09-11
WO2006113631A2 (en) 2006-10-26
IL186721A0 (en) 2008-02-09
WO2006113631A3 (en) 2006-12-14
EP1877042A2 (en) 2008-01-16
KR20080042039A (ko) 2008-05-14
CA2605183A1 (en) 2006-10-26
AU2006236497A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
MX2007012947A (es) Composiciones biomejoradas.
UA94052C2 (uk) Похідні піридазину
IL243574B (en) A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
MX2010002191A (es) Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
IN2012DN03180A (es)
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
UA107649C2 (uk) Ізоксазол-ліганди метаботропного рецептора глутамату та їх застосування як потенціаторів
MX2009003246A (es) Análogos de ghrelina sustituidos en el terminal n.
TW200626558A (en) Indazolone derivatives
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
PL2120890T3 (pl) Peletki powlekane
UA96994C2 (ru) Производные 7-алкинил-1,8-нафтиридонов, способ их получения и их применения в терапии
IN2012DN00954A (es)
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
MX2009005984A (es) Formulaciones con alta concentracion de proteina que contiene manitol.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
GEP20146061B (en) Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl- 1,2-dihydroquinoline derivative having substituted oxy group
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
PL2165702T3 (pl) Stabilne i łatworozpuszczalne kompozycje cyleksetylu kandesartanu wytwarzane granulowaniem na mokro
UA101627C2 (uk) Покривна композиція, що містить полідекстрозу, спосіб її одержання і застосування для нанесення покриття на тверді форми для перорального прийому
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists